Skip to main content

Table 2 Reduction in the occurrence of dermatologic changes in dogs with generalized demodicosis after treatment with either Bravecto™ or Advocate®

From: Efficacy of orally administered fluralaner (BravectoTM) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs

Bravecto ™ : occurrence of lesions on days before and after treatment (dogs were treated on Day 0: number of dogs/number of dogs per group)
Clinical sign Day −4 Day 28 Day 56 Day 84
Erythematous patches 62.5% (5/8) 37.5% (3/8) 12.5% (1/8) 12.5% (1/8)
Crusts, casts or scales 100% (8/8) 62.5% (5/8) 62.5% (5/8) 12.5% (1/8)
Advocate®; occurrence of lesions on days before and after initial treatment (dogs were treated on Days 0, 28 and 56 a : number of dogs/number of dogs per group)
Clinical sign Day −4 Day 28 Day 56 Day 84
Erythematous patches 87.5% (7/8) 50% (4/8) 0% (0/8) 0% (0/7)b
Crusts, casts or scales 100% (8/8) 100% (8/8) 37.5% (3/8) 42.9% (3/7)b
  1. aSkin assessments were performed before treatment.
  2. bOn day 59 one dog had to be euthanized due to the presence of a malign tumour in the stomach.
Back to article page

Parasites & Vectors

ISSN: 1756-3305

Contact us